Takeda Pharmaceutical Company Limited (4502.T)
Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
At close: 03:15PM JST
| Previous Close | 4,143.00 |
| Open | 4,160.00 |
| Bid | 4,121.00 x 0 |
| Ask | 4,126.00 x 0 |
| Day's Range | 4,121.00 - 4,161.00 |
| 52 Week Range | 3,900.00 - 4,873.00 |
| Volume | |
| Avg. Volume | 4,414,406 |
| Market Cap | 6.472T |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 36.74 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 188.00 (4.54%) |
| Ex-Dividend Date | Mar 28, 2024 |
| 1y Target Est | N/A |
- Zacks
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Zacks
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Zacks
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
© 2024 Yahoo. All rights reserved.